JG
XERS icon

Jefferies Group’s Xeris Biopharma Holdings XERS Stock Holding History

Jefferies Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-91,800
Closed -$244 – 1582
2020
Q2 		$244 Buy
+91,800
New +$320K ﹤0.01% 1047
2019
Q4 		– Sell
-11,698
Closed -$115K – 3060
2019
Q3 		$115K Buy
+11,698
New +$131K ﹤0.01% 2481

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's XERS Position: Q3 2020 in Review

Jefferies Group sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 91,800 shares — an estimated $244 sold.

Jefferies Group first reported a position in XERS in Q3 2019 and held it in 2 quarters. The position peaked at $115K in Q3 2019. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • Jefferies Group reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 91,800 Xeris Biopharma Holdings shares in Q3 2020, an estimated $244.
  • Jefferies Group first reported a position in Xeris Biopharma Holdings in Q3 2019 and held it in 2 quarters.
  • Jefferies Group's Xeris Biopharma Holdings position peaked at $115K in Q3 2019.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.